Wegovy 28% weight loss in trial

Weight-loss drugs are now a dose race as much as a molecule race. That is the backdrop for today’s Wegovy news. Novo Nordisk used the European Congress on Obesity in Istanbul, running May 12 to May 15, 2026, to show fresh analyses from STEP UP — its trial of a higher 7.2 mg semaglutide dose. (sciencehub.novonordisk.com) The pitch is simple: some people on the bigger dose lose a lot more weight, and they get there faster. ### What actually changed? The new thing is not a brand-new trial result. The main STEP UP study was already out — a phase 3b trial in 1,407 adults with obesity, without diabetes, randomized over 72 weeks to semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo. (biospace.com) Today’s update is a post hoc look at who responded early and how body composition shifted. (fda.gov) ### What is the 28% number? It is not the average for everyone on high-dose Wegovy. The 27.7% figure comes from “early responders” on 7.2 mg — people who had already lost at least 15% of body weight by week 24. That subgroup then averaged 27.7% loss by week 72. Across all participants, the earlier STEP UP result was lower: 20.7% average loss on 7.2 mg, versus 17.5% on the standard 2.4 mg dose. (sciencehub.novonordisk.com) ### Why does “early responder” matter so much? Because it tells you the splashiest number is a filtered one. Novo is basically saying: if a patient is already doing unusually well at 6 months, that patient may keep doing very well through 72 weeks. That can be clinically useful, but it is also a classic way to make a drug look stronger than the all-comers average. (sciencehub.novonordisk.com) Early responders were about 27% of people on 7.2 mg in reporting around the analysis. ### What about fat versus muscle? Novo also highlighted body-composition data. The company said about 84% of the weight lost with semaglutide 2.4 mg and 7.2 mg was fat mass, while muscle function was preserved and muscle health improved. That is important because rapid weight loss always raises the same question — are people getting leaner, or just smaller? (biospace.com) The catch is that this framing still comes from company-linked analyses, so doctors will want the methods and independent scrutiny, not just the headline. ### Is the higher dose harder to tolerate? Somewhat, yes. In STEP UP, gastrointestinal side effects were more common with 7.2 mg than with 2.4 mg — 70.8% versus 61.2%. Dysaesthesia was also more common. But serious adverse events were not higher on the bigger dose in the same direction people might expect: 6.8% on 7.2 mg, 10.9% on 2.4 mg, and 5.5% on placebo in the trial summary Novo posted. (biospace.com) ### Why is Novo pushing this now? Because the obesity market is now a straight-up fight with Eli Lilly. Lilly’s head-to-head SURMOUNT-5 result showed Zepbound beating standard-dose Wegovy, with 20.2% average weight loss versus 13.7% at 72 weeks. A 7.2 mg Wegovy that averages 20.7% in STEP UP does not erase that comparison — different trials, different setups — but it gives Novo a much better counterpunch than the old 2.4 mg story. (biospace.com) ### Can patients get this dose now? In the U.S., yes — a higher-dose 7.2 mg Wegovy version won FDA approval in March 2026, and Novo launched it in April. So this is not just conference theater. It is marketing support for a product Novo is already trying to put in front of prescribers and payers. (sciencehub.novonordisk.com) ### So what should readers take from it? The clean read is this: high-dose Wegovy looks meaningfully stronger than standard Wegovy, and a subset of patients can lose an eye-popping amount of weight. But the 28% figure is not the average patient result. It is the best-looking slice of the trial. The real story is narrower and still important — Novo found a way to make semaglutide more competitive without inventing a new drug. (biospace.com) (fda.gov) (prnewswire.com)